BioNTech SE
BNTX
$92.80
-$0.87-0.93%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -59.27% | -29.55% | -16.73% | 29.76% | 113.67% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -59.27% | -29.55% | -16.73% | 29.76% | 113.67% |
| Cost of Revenue | 27.70% | -7.09% | 35.80% | -11.85% | 34.71% |
| Gross Profit | -95.31% | -48.56% | -30.24% | 36.74% | 182.20% |
| SG&A Expenses | 44.80% | 36.36% | 80.14% | 4.93% | -21.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 684.90% | 282.36% | 355.39% | 113.27% | -112.82% |
| Total Operating Expenses | 39.36% | 21.35% | 28.10% | 34.84% | -33.19% |
| Operating Income | -99.16% | -38.73% | -308.49% | -267.91% | 52.84% |
| Income Before Tax | -114.48% | -39.09% | -182.45% | -83.45% | 47.30% |
| Income Tax Expenses | -136.78% | -33.37% | 103.22% | 244.13% | -948.81% |
| Earnings from Continuing Operations | -113.55% | -39.50% | -228.35% | -115.41% | 49.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -113.55% | -39.50% | -228.35% | -115.41% | 49.54% |
| EBIT | -99.16% | -38.73% | -308.49% | -267.91% | 52.84% |
| EBITDA | -55.36% | -23.93% | -204.75% | 48.52% | 56.15% |
| EPS Basic | -103.68% | -32.37% | -226.40% | -115.56% | 49.79% |
| Normalized Basic EPS | -100.14% | -27.62% | -167.13% | -78.14% | 50.12% |
| EPS Diluted | -103.68% | -32.37% | -226.70% | -115.76% | 49.79% |
| Normalized Diluted EPS | -100.14% | -27.62% | -167.13% | -77.87% | 50.12% |
| Average Basic Shares Outstanding | 4.85% | 5.38% | 1.55% | -1.00% | 0.50% |
| Average Diluted Shares Outstanding | 4.85% | 5.38% | 1.55% | -2.21% | 0.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |